Drug Profile
Leucine/sildenafil/metformin companion diagnostic - NuSirt Biopharma/OWL Metabolomics
Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator NuSirt Biopharma
- Developer NuSirt Biopharma; One Way Liver Genomics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-alcoholic fatty liver disease
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Non-alcoholic-fatty-liver-disease(Diagnosis) in USA
- 23 Sep 2016 Investigation in Non-alcoholic fatty liver disease (Diagnosis) in USA (unspecified route)
- 20 Sep 2016 NuSirt Biopharma and One way liver metabolomics collaborates to develop diagnostic tools for drug, NS 0200